Cargando…
Preclinical Evaluation of a (64)Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optim...
Autores principales: | Métivier, Cassandra, Le Saëc, Patricia, Gaschet, Joëlle, Chauvet, Catherine, Marionneau-Lambot, Séverine, Hofgaard, Peter O., Bogen, Bjarne, Pineau, Julie, Le Bris, Nathalie, Tripier, Raphaël, Alliot, Cyrille, Haddad, Férid, Chérel, Michel, Chouin, Nicolas, Faivre-Chauvet, Alain, Rbah-Vidal, Latifa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385603/ https://www.ncbi.nlm.nih.gov/pubmed/37514004 http://dx.doi.org/10.3390/pharmaceutics15071817 |
Ejemplares similares
-
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019) -
Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018) -
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
por: Gouard, Sébastien, et al.
Publicado: (2020) -
From bench to bedside: (64)Cu/(177)Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications
por: Gnesin, Silvano, et al.
Publicado: (2023) -
Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies
por: Berdal, Marion, et al.
Publicado: (2020)